D. Casula

发表

Evaluation of an Adaptive Seamless Design for a Phase II/III Clinical Trial in Recurrent Events Data to Demonstrate Reduction in Number of Acute Exacerbations in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A. Callegaro, D. Casula, Phoebe Nakanwagi, 2020 .

Safety assessment and immunogenicity of a cell-culture-derived influenza vaccine in adults and elderly subjects over three successive influenza seasons

A. Izu, D. Casula, N. Groth, 2012, Human vaccines & immunotherapeutics.

Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study

G. Di Maro, M. Janssens, T. Schwarz, 2022, Respiratory Research.

Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adults

P. Chanthavanich, D. Casula, A. Arora, 2018, PLoS neglected tropical diseases.

Impact of prior or concomitant seasonal influenza vaccination on MF59‐adjuvanted H1N1v vaccine (Focetria™) in adult and elderly subjects

R. Gasparini, D. Casula, M. Pellegrini, 2010, International journal of clinical practice.

Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial.

C. Brightling, W. MacNee, J. Hedner, 2019, Vaccine.

Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine in healthy adolescents in Korea--A randomised trial.

Y. Choe, Hyunju Lee, D. Casula, 2016, Vaccine.

A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.

G. Leroux-Roels, F. von Sonnenburg, D. Casula, 2012, Vaccine.

A detailed analysis of possible efficacy signals of NTHi-Mcat vaccine against severe COPD exacerbations in a previously reported randomised phase 2b trial.

Fernando Ulloa-Montoya, D. Casula, A. Arora, 2022, Vaccine.

Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.

R. Bugarini, A. Podda, T. Tsai, 2009, The Journal of infectious diseases.

Associations of the correlates of protection and implication on the statistical power for demonstrating non-inferiority: application of a re-sampling method on a large phase III influenza vaccine clinical trial.

R. Bugarini, A. Podda, D. Casula, 2010, Vaccine.

CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study.

M. Franceschi, G. Bottini, E. Scarpini, 2013, Current Alzheimer research.

Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial.

E. Kerwin, H. Watz, F. Maltais, 2022, The Lancet. Respiratory medicine.

CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo-Controlled Study.

M. Franceschi, G. Bottini, E. Scarpini, 2013, Current Alzheimer research.

Long-term immunogenicity and safety of a non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine: 4-year follow-up of a phase 1 multicentre trial

G. Leroux-Roels, G. Di Maro, D. Casula, 2021, Vaccine: X.

Pharmacokinetics and Pharmacodynamics of CHF5074 After Short-term Administration in Healthy Subjects

F. Fiorentini, L. Calzà, B. Imbimbo, 2013, Alzheimer disease and associated disorders.

Stepping-across controlled asthmatic patients to extrafine beclometasone/formoterol combination.

P. Chanez, J. V. van Noord, N. Barnes, 2013, Pulmonary pharmacology & therapeutics.

Phase III, randomized controlled trial to evaluate lot consistency of a trivalent subunit egg-based influenza vaccine in adults.

D. Casula, Luis Rivera, N. Groth, 2012, Vaccine.

Immunogenicity and safety of the non-typable Haemophilus influenzae–Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial

V. Anttila, A. Borobia, O. Launay, 2023, Human vaccines & immunotherapeutics.